RADIOCHEMISTRY--CORE

放射化学--核心

• 批准号: 6102382
• 负责人: Janet F. Eary
• 金额: $ 40.93万
• 依托单位: FRED HUTCHINSON CANCER RESEARCH CENTER
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-07-12 至 2000-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6102382
• 关键词: biomedical facility; nuclear medicine; radiochemistry; radiopharmacology

In core B, nuclear imaging and radiochemistry services for all the projects will be provided. In pre-clinical studies, the laboratory will evaluate each antibody lot, as well as new antibodies for tolerance to labeling at trace, as well as high specific activity levels for therapy. The laboratory will also prepare and perform quality control tests on I- 131 trace labeled specific antibodies, and I-125 labeled non-specific antibodies for use in patients. For these activities, the Core will prepare high specific activity therapy doses for patient treatment. As a part of all these procedures, all aspects of quality control for the radiopharmaceuticals will be maintained and documented. Members of the Core will also prepare radiopharmaceuticals for patient use if new, alternative radiolabeling methods are introduced from Project 3. The core will also support nuclear medicine imaging procedures to observe biodistribution of radiolabeled antibody in patients and translate that data into radiation dose estimates for treatment. Members of the core will supervise the administration of therapy doses of radiolabeled antibodies.

在核心B中，为所有 将提供项目。在临床前研究中，实验室将 评估每个抗体批次，以及新抗体对 示踪标记，以及用于治疗的高比活度水平。 实验室还将准备和进行关于i- 131示踪标记的特异性抗体和I-125标记的非特异性抗体 病人使用的抗体。对于这些活动，核心将 准备用于患者治疗的高比活度治疗剂量。作为一名 所有这些程序的一部分，所有方面的质量控制 放射性药品将得到维护和记录。委员会成员 如果是新的，CORE还将准备供患者使用的放射性药物， 替代的放射性标记方法从项目3中引入。核心 还将支持核医学成像程序观察 放射性标记抗体在患者体内的生物分布及其翻译 将数据转化为辐射剂量估计用于治疗。核心成员将 监督治疗剂量的放射性标记抗体的管理。